Neste trabalho é proposto o primeiro modelo por homologia para a nucleosídeo hidrolase de Leishmania donovani construído a partir das estruturas das nucleosídeo hidrolases de Crithidia fasciculata e de Leishmania major. Usando as informações de interação entre o inibidor p-aminofeniliminoribitol e a nucleosídeo hidrolase de Crithidia fasciculata foram planejados dois novos potenciais inibidores, os quais apresentam novas interações com alguns resíduos da bolsa hidrofóbica do sítio ativo do modelo. Simulações por dinâmica molecular dos protótipos ancorados nos sítios ativos do modelo e das enzimas usadas como moldes, mostraram que, diferente do p-aminofeniliminoribitol, eles permaneceram ancorados nos sítios ativos das três enzimas ao longo de toda a dinâmica, interagindo fortemente com os aminoácidos da bolsa hidrofóbica.In this work we propose the first homology model for nucleoside hydrolase from Leishmania donovani, built based on the crystallographic structures of Crithidia fasciculata and Leishmania major nucleoside hydrolases. We used the interaction information from the crystallographic model of the enzyme of C. fasciculata in complex with the inhibitor p-aminophenyliminoribitol, to design two new potential inhibitors, which present new interactions with some residues of the hydrophobic pocket of the model active site. Molecular dynamics simulations of the prototypes inside the active sites of the model and the template enzymes showed that, differently from p-aminophenyliminoribitol, they remained tightly bound inside the active sites, interacting strongly with the amino acids from the hydrophobic pocket.
Keywords: visceral leishmaniasis, Leishmania donovani, metalloproteins, homology modeling, molecular dynamics
IntroductionAccording to the World Health Organization (WHO), leishmaniasis is a threat for 350 million people in 88 countries, where 72 of those are developing countries. WHO also estimates that 12 million people in the world are infected and 2 million new cases appear annually, despite the official report of only about 600,000 new cases every year. 1 It is clear that leishmaniasis is one of the most important parasitic diseases, which is caused by protozoan of the Leishmania genus. This disease affects humans in four different forms with a broad range of clinical manifestations: visceral, mucocutaneous, cutaneous and diffuse cutaneous leishmaniasis. [1][2][3][4] Visceral leishmaniasis, also known as "kala-azar", is considered the most dangerous form of this disease, being fatal in 100% of the untreated cases 1 and is caused by the L. donovani complex.
4The search for prevention against leishmaniasis infection includes vaccines with weakened and genetically modified strains of the parasite and recombinant antigens 5 or its encoding DNA. 6 The only preventive treatment for leishmaniasis available today is the canine vaccine 65 França et al. Vol. 19, No. 1, 2008 Leishmune ® . 7 An efficient human vaccine is not available yet. Accordingly, the most effective way to combat leishmaniasis stil...